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INTRODUCTION
Demyelinating diseases form a class of disorders characterized by loss or 
attenuation of the myelin sheath in the relative absence of neuronal loss and it can 
occur in both in peripheral and central nervous systems.
The myelin sheath provides a  high resistance,  low capacitance insulation 
between  the  sites  of  action  potential  electrogenesis,  the  node  of  Raniver.   It 
conducts impulses from one node to another in saltatory manner and therefore its 
loss is accompanied by significant conduction abnormalities.
The demyelinating diseases have been subdivided by various authors in a 
variety of ways. One such classification is as follows.
DISEASES OF MYELIN
Autoimmune
Acute disseminated encephalomyelitis
Acute hemorrhagic leukoencephalopathy
Multiple sclerosis
Infectious
Progressive multifocal leukoencephalopahty
Toxic / Metabolic
Carbon monoxide
Vitamin B12 deficiency
Mercuty intoxication (Minamata disease)
Alcohol / tobacco amblyopia
Central pontine myelinolysis
Marchiafava-Bignami syndrome
Hypoxia
Radiation
Vascular
Binswanger’s disease
Hereditary Disorders Of Myelin Metabolism (Dysmyelinating)
Adrenoleukodystrophy
Metachromatic leukodystrophy
Krabbe’s disease
Alexander’s disease
Canavan-Van Bogaert – Bertrand disease
Pelizaeus – Merzbacher disease
Phenylketonuria
REVIEW OF LITERATURE
Multiple  sclerosis  has  been the  subject  of  study  by workers  all  over  the 
world. It is caused by an inflammatory demyelinating process in the CNS.  More 
than 250 prevalence surveys have been carried out serving as the basis for the 
delineation of geographical risk for MS.
High frequency areas of the world, with the current prevalence of 60 per 
100,000 or more, include all of Europe, Southern Canada, the Northern United 
Status, New Zealand and Southeast Australia.
Medium frequency areas of 5 to 25 per 100,000 comprise most of Australia, 
the Southern US, the Mediterranean basis and white population of South Africa.
Low risk areas of less than 5 per 100,000 include most of Asia and all of 
Africa.
One  possible  conclusion  is  that  MS is  a  location  related  illness,  with  a 
latitude gradient with some notable exceptions like Japan.
S.No
.
Country Latitude Prevalence
1. Iceland 65 N 78.5
2. UK (Shetlands) 61 N 129
3. Canada 50 N 30
4. Yugoslavia 45 N 43.7
5. Japan 44 N 2.5
6. France 43 N 39.6
7. USA 42 N 41
8. Spain 39 N 17.2
9. Greece 40 N 38
10. Algeria 37 N 10
11. Malta 36 N 4
12. Asia 36 N 3
13. Israel 32 N 9.5
14. Kuwait 30 N 9.5
15. Hong Kong 23 N 0.8
16. Bombay 19 N 26
Review of previous Indian literature on MS indicated that MS comprises 
0.05 to 1.5% of the total neurologic inpatients.  On an average, 1.6 to 5.4 new 
cases of MS are seen at various centres per year (Jain and Maheswari et al 1985).
However  two epidemiological  studies  among Parsis  living in  Bombay & 
Pune found a crude prevalence of 21 cases per 100,000 parsis in Bombay and 58 
per 100,000 in Pune (Bharucha et al 1988, Wadia et al 1990).
Previous Indian literature on MS showed male preponderance in most series, 
the mean age at onset in third and early fourth decade.
When  compared  to  MS  in  Western  countries,  the  Indian  cases  show  a 
relatively high incidence of optic nerve involvement both at onset and during the 
course of disease (Jain & Maheswari et al 1985).  Neuromyelitis optica is also seen 
frequently.  Neurological manifestations are protean being determined by varied 
location and predilection for certain portions of CNS resulting in complexes of 
signs and symptoms and radiological appearance  that can often be recognized as 
characteristic of MS (Olliver et al 1824). Cruveitier published  gross pathological 
descriptions of MS together with clinical case descriptions.  Pierre Marie was the 
first  to  suggest  on  infectious  cause  of  MS in  1884,  a  hypothesis  that  is  still 
debated.  Toxins were also considered to be responsible in the early 1900s.  A 
major advance towards understanding of demyelinating disease was discovery of 
experimental. Allergic Encephalomyelitis (EAM) by Rivers in 1955.
All high and medium risk areas are predominantly white population and MS 
is the white man’s burden.  Aside from geography, age, sex and race risk factors 
for MS include, high socio economic status and urbanization atleast in some series 
(Kurtzke et al 1991).
Evidence that genetic factors have a substantial effect on susceptibility to 
MS is unequivocal (John et al 2000).  Migrant studies indicate that on the whole, 
the  migrants  retain  the  risk  of  their  birth  place.   The  migration  data  plus  the 
geographic  distribution  and  clustering  serve  to  define  MS  as  an  acquired, 
exogenous, environmental disease and one that is ordinary acquired in adolescence 
with a long incubation period before the onset of symptoms.  Female to male ratio 
is 1.5  :  1 in many studies.
MS in India has low prevalence.  However recent epidemiological studies 
indicate that atleast in some parts of India, there is higher prevalence.
No. Region Study M.S Devics Autops
y 
proven
1. Bombay Singhal 1957-86 127 14 2
2. Chandigarh Chopra 1968-77 38 5 3
3. Delhi Ahuja & roy 1973-79 18 - 1
4. Vellore Mathew 1965-70 17 - -
5. Bangalore Gouri devi & Nagaraja 
1961-80
42 8 1
6. Andhra 
Pradesh
JMK  murthy  &  MVR 
Reddy  1979-85
26 6 -
Clinically definite MS as a percentage of total neurological admissions to 
various hospitals has varied from 0.22 in vellore (Mathew), 0.32 in Delhi (Verma), 
0.4 in Bombay (Singhal), 0.6 in Chandigarh (JS Chopra), 0.68 in Andhrapradesh 
(Murthy) 0.35 in Karnataka (Gauri devi & Nagaraja).
Male preponderance was noted in majority of the series from India (Chopra 
et al 1980, Gourie Devi & Verma).  However female preponderance was noted in 
one series from Bombay (Singhal et al 1987).  Opticospinal and optico spino brain 
stem forms were the forms seen in India and other Asian countries (Chopra, Gouri, 
Singhal, Stibastic 1985).
The precise cause of MS is still not known.  We also don’t know the reasons 
for the rare occurrence of MS in India and other oriental countries.
The  explanation  may  lie  in  genetic  or  environmental  features  or  both. 
Milton Alter et al 1977 has suggested that in countries with low prevalence of MS, 
viral and bacterial infection are more frequent and people are more exposed to 
these at early age which provide them with effective immunity that reduces their 
risks of acquisition of MS from a latent infection.
S. Bansil, B.S. Singhal et al 1996 studied the various aspects of M.S. and 
compare it with US patients.
Region 
involved
Parameter India US P value
Cerebral MRI 58/66 92/99 NS
Spinal MRI
Clinical
17/38
71/81
19/34
96/06
NS
NS
Optic VEP
Clinical
60/72
68/71
34/56
62/106
< 0.005
< 0.0002
Brain stem MRI
BERA
Clinical
22/66
11/64
44/81
34/98
10/47
71/100
NS
NS
NS
Cerebellum MRI
Clinical
11/66
37/81
20/98
54/106
NS
NS
This implied visual symptoms both by VEP and clinical criteria was more 
frequent in Indian patients.  NMO variant was more reported to be more common 
in Indian patients as well as oriental Asian population. (Shibusaki et al 1978).
Diagnostic Criteria :`
Jean – Martin charcot, in 1868, first proposed nystagmus, intention tremor 
and scanning speech and Otto Marburg, in 1936 proposed Ulthoff sign, negative 
abdominal  reflexes  and  pyramidal  signs  as  diagnostic  criteria  which  are  now 
obsolete.
The criteria by Sydney Allison and Harold Millar et al in 1954, Schumacher 
et al in 1965 and Mc Aplane et al in 1972 are also not in use now.
Poser et al in 1983, proposed a criteria as follows.
Category Attack Clinical  
evidence
Para 
clinical
CSF
OCB / IgG
Clinically Definite MS
  CDMS    A1
  CDMS    A2
2
2
2
1 and    1
Lab supported MS
  LSMS  B1
  LSMS  B2
  LSMS  B3
2
1
1
1
2
1
or
and
and
   1
  -
   1
+
+
+
Category Attack Clinical  
evidence
Para 
clinical
CSF
OCB / IgG
Clinically Probable MS
  CPMS   C1
  CPMS   C2
  CPMS   C3
2
1
1
1
2
1 and 1
Lab supported 
probable MS 
      LSPMS 2 +
Revised  McDonald  et  al  (2005)  diagnostic  criteria  for  multiple  sclerosis  is  as 
follows.
Clinical (attacks)  Objective Additional requirement
 2  or  more  2 or more None
 2  or  more 1  Disemination in space by MRI or 2 or 
 more MRI lesion consistent with MS 
 plus positive CSF or await further 
 clinical attack implicating other size
1   2 or more  Dissemination in time by MRI or 
 second attack
1     1 Dissemination in space by MRI or 2 or 
 more MRI lesions consistent with MS
 plus positive CSF and
 Dissemination in time by MRI or 
 second attack
0 (Progression 1 or more Disease progression for 1 year and 2 
from onset) out of 3 of the following
1)Positive brain MRI (9T2 lesions or 4 
 or more T2 lesions with positive VEP)
2) Positive spinal cord MRI (2 or more 
    focal T2 lesions)
3) Positive CSF
Clinical features :
Posner et al (1995) proposed definitive symptoms lasting for atleast 24 hours 
and possible symptoms which must be followed by definite symptoms within 2 
years in order to be onset of markers.  Clinical features suggestive of MS are, 
onset  between  ages  15  and  50,  involvement  of  multiple  areas  of  CNS,  optic 
neuritis,  Lhermitte’s sign, inter nuclear ophthalmoplegia, fatigue and worsening 
with elevated body temperature.  Onset before 10 and after 60, involvement of 
PNS,  hemianopsias,  rigidity  and  sustained  dystonia,  cortical  deficits  such  as 
aphasia, apraxia and neglect, deficit developing within mints and early dementia 
are clinical features not suggestive of MS. Initial symptoms by Weinshenker et al 
(1989) in their study of 1096 cases included optic neuritis 17.2%, sensory 45.4% 
motor 20.1%, Diplopia 0.9% and cerebral 13.2%.
Pathology :
John et al (2000) found that MRI and MRS may be helpful in characterizing 
the underlying pathological process in MS. Changes in number and volume of 
lesions in T2 MRI are sensitive but nor specific markers of disease activity and 
response to treatment,  Miller et al 1998.  The pathological hall mark of MS is the 
cerebral or spinal plaque which often have a hard or rubbery consistency and small 
size (1 to 2 cm) but confluent plaque can also occur.  Histological examination 
reveals  perivascular  infiltration  of  lymphocytes,  especially  T  cells  and 
macrophages with occasional plasma cells.   The fate of oligodendroglia in MS 
lesions is disputed, Consensus opinion is that it is reduced at plaque centre and 
preserved or  increased at  periphery.   Pathologically  types I  & II  appear  to  be 
mostly inflammatory with retention of active oligodendrocytes in comparable to 
types III & IV which are mainly necrotic.  Recent pathological studies demonstrate 
that  the  extent  of  remyelination  can  be  quite  extensive,  even  in  patients  with 
progressive disease. (Patrikios et al  2006).
Course :
Relapsing  remitting,  secondary  progressive,  primary  progressive  and 
progressive relapsing are four clinical patterns of MS.  Reenmaker and Anderson 
et al 1993 found that 66% at onset had relapsing and remitting, 15% relapsing and 
progressive and 19% progressive at  onset  and in follow up for 25 years,  80% 
become progressive and 15% died.
Investigations :
Palace et  al  2001,  proposed that MRI, Evoked Potentials and CSF Oligo 
Clonal  Bands  are  3  main  investigations.  The  white  matter  lesion  seen  on  the 
imaging correlate well with macroscopic plaque pathologically Ormeod et al 1987.
Gadolinium enhancement is seen with new early active lesions due to Blood 
Brain  Barrier  disruption  and  it  usually  lasts  for  4-6  weeks.   T1  black  holes 
correlate with tissue destruction including loss of axons, Van walderveen et al, 
1997.
Patey  et  al  1977,  proposed 3  or  more  T2 hyperintense  lesions  with  one 
bordering lateral ventricle to diagnose MS.  A positive MRI in revised criteria by 
Mc Donald et al 2005, include three out of four of the following.
1. One Gd-enhancing brain or cord lesion or nine non Gd-enhancing brain 
or cord lesion in T2 MRI
2. One or more brain infratentorial or cord lesions
3. One or more juxtacortical lesions
4. Three or more periventricular lesions.
EVOKED POTENTIALS 
VEP 
Delayed but well preserved wave form is positive VEP.  Of 744 patients, 
reported to have no history or clinical findings of optic neuritis, 51% had pattern 
shift VEP abnormalities ranging from a high of 93% (Halliday et al 1973) to a low 
of 34% (Purves et al 1981.)
Chiappa  in  1997  showed  BAEP  abnormalities  in  67%,  41%  and  30% 
patients of definite, probable and possible MS patients and SEP in 77%, 67% and 
49% patients respectively.
CSF 
The frequency of abnormal Oligo Clonal Bands in definite MS was 90%, in 
isolated MS was 50%, in transverse myelitis was 30% and in normal control was 
2% -  Andersen et al 1994.
Acute Disseminated Encephalo Myelitis  (ADEM)
It  is  a  demyelinating  syndrome  that  occurs  in  association  with  an 
immunization or vaccination.  The clinical presentation more common in children 
include, simultaneous bilateral optic neuritis, loss of consciousness, loss of Deep 
Tendon Reflexes and retained abdominal reflexes in presence of babinski’s sign, 
central body temperature of greater than 100o F and severe shooting limb pains.
A feature of ADEM is that majority of the T2 lesions show enhancement 
suggesting they are of recent onset, consistent with a monophasic illness.  Hurst, 
first postulated the immune response invoked by neural tissues in brain.  In 1935, 
Rivers and Schwantker inoculated monkeys with normal brain tissue and produce 
Experimental  Allergic  Encephalitis  which  is  the  prototype  experimental 
autoimmune disease.  In recurrent ADEM, stereotyped features follows the partial 
or complete recovery.  In multiphasic ADEM, differing symptoms occur and serial 
MRI  is  needed  to  distinguish  this.   Lesions  of  ADEM tend to  resolve  during 
follow up, complete resolution in one thirds and partial  in others (Hynson and 
Dale et al)
A comparison of 3 major case series of ADEM is as follows
Factor Hynson (2001) Dale (2000) Schwartz (2000)
Age 2 – 16 3 – 15 19 – 61
Prior inf % 77 74 76
Prior vaccine 2/31 2/28 -
Disease evolution 1-42 days 0-31 days 0-14 days
Headache % 45 58 Not given
Fever % 52 43 15
Meningism % 26 31 15
Altered sensorium% 68 69 19
Optic neuritis% 13 29 Not given
Cranial nr palsies% 45 51 Not given
Pyramidal signs % 23 71 77
Sensory deficits % 3 17 65
Ataxia % 65 49 38
Aphasia % 26 0 8
Seizures % 13 0 4
Extrapyramidal % 0 2 0
CSF pleocytosis % 62 64 81
OCB% 3 29 58
MRI white matter % 90 91
MRI periventricular % 29 44 54
Thalamus % 32 41 15
Basal ganglia % 39 28 Not given
Brain stem % 42 56 57
Spinal cord % 16 28 Not given
Corpus collosum % 29 Not given 23
Gd enhancement % 90 11 71
Follow up MRI 25% Normal
75% decrease in 
size of lesion
37% normal
53% partially 
improved
10% unchanged
26% Normal
55% partially 
resolved
15% new lesions
In  NIMHANS  study,  during  the  period  Jan  1997  –  2003,  mean  age  of 
presentation was 22 years and 50% were less than 15 years old.  Non specific 
infection was the  commonest  antecedent  event.   Gray matter  involvement  was 
common (89%).  Mortality was 16% and causes of death were bronchopneumonia, 
sepsis and autonomic dysfunction and children had better prognosis than adults.
GUILLIAN-BARR`E SYNDROME 
The term GBS defines a recognizable clinical entity that is characterized by 
rapidly  evolving  symmetrical  limb  weakness,  loss  of  tendon  reflexes,  mild  or 
absent  sensory  signs  and  variable  autonomic  dysfunctions.  It  has  become  the 
leading cause of acute flaccid paralysis after the eradication of poliomyelitis from 
many countries.
In  1859,  Jean  Baptiste  Octave  Landry  described  this  entity  as  acute 
ascending paralysis.
In 1916, Guillain,  Barre and Strohl emphasized the main clinical features of 
GBS  as  motor  weakness,  areflexis,  paresthesia  and  minor  sensory  loss  and 
albumino  cytological  dissociation  in  CSF.   In  1956,  Fisher’s  syndrome  was 
described.   Young  et  al  in  1975,  described acquired  dysautonomic  features  in 
GBS.  In 1990 Asbury and Cornblath proposed a laboratory and clinical criteria 
for GBS.
Incidence was 4 per lakh population as per Kaplan et al.  In 1992, Ropper et 
al (Massachusether General Hospital study) reported  the mean age of occurrence 
of GBS was 39 years with bimodal peak in 16-25 years and 45-60 years, Dowling 
et al in their study found no seasonal cluster.
Antecedent illness was found in two thirds of cases which were preceded by 
average of 11 days in MGH study.
Rabies, BCG, T.T, influenza, measles, mumps, rubella hepatitis B and polio 
was found to be antecedent illness by Applebaum et al 1953, 1994.  Serological 
evidence of campylobacter was found in 38% to 0% as per Kalder and Spend et al 
1984 study.
Pathogenesis :
The bulk  of  experimental  and clinical  evidence  suggests  that  GBS is  an 
organ-specific, immune-mediated disorder caused by a synergistic interaction of 
cell mediated and humoral immune response to still  incompletely characterized 
peripheral nerve antigens (Kieseier et al, 2006).
At the onset of disease, activated T cells play a major role in opening the 
blood nerve barrier  to allow circulating antibodies to gain access  to peripheral 
nerve  antigens.   T-cell  activation  markers  (interleukin-6,  interleukin-2,  soluble 
interleukin-2 receptor, and interferon) and TNF- α,  a proinflammatory cytokine 
released by      T cells and macrophages, particularly IL-23 (Hu et al 2006), are 
increased in patient serum.
Diagram showing Mechanism of immune injury to nerve fibres in AIDP
Several  observation  indicate  that  humoral  factors  also  participate  in  the 
autoimmune attack on peripheral nerve myelin, axons, and nerve terminals :  1) 
immunoglobulins and complement can be demonstrated on myelinated fibers of 
affected patients by immunostaining ;  2) MFS and AMAN are strongly associated 
with specific antiganglioside antibodies ; 3) Serum from MFS and AMAN patients 
contain IgG antibodies that block neuromuscular transmission in a mouse nerve-
muscle  preparation  ;  4)  complement  C1-fixing  antiperipheral  nerve  myelin 
antibody can be detected in the serum of patients during the acute phase of GBS ; 
5) Intraneural injection of GBS serum into rat sciatic nerve results in secondary T 
cell infiltration of the injection site at the time of the appearance of the hind limb 
weakness, and 6) Plasmapheresis or immunoglobulin infusions result in clinical 
improvement.
Certain  C.  jejuni  strains  associated  with  axonal  GBS  and  MFS  variants 
contain  GM like  epitopes  in  their  polysaccharide  coats.   Anti  GM and  GQ1b 
antibodies that cross react to these lipopolyaccharide epitopes are found in a high 
proportion of patients with AMAN and MFS and some patients with GBS.
The  antiganglioside  antibodies  obtained  from  AMAN  and  MFS  patients 
block neuromuscular transmission in an in vitro nerve muscle preparation.  The 
blocking  activity  of  these  IgG  antibodies  can  be  neutralized  by  intravenous 
immuno globulin (Buchwald et  al  2002).  Furthermore,  rabbits immunized with 
GM,  develop  AMAN,  thereby  fulfilling  the  postulates  for  confirming  an 
autoimmune pathogenesis (Sheikh and Griffin, 2001).  
Clinical features :
In typical GBS, Ropper et al 1992 found weakness in 60%, paresthesia in 
80%, both in 30%, areflexis in 70%, hyporeflexis in 30% of patients.
The pattern of weakness noted by Ropper et al 1992 was ascending in 54%, 
descending in 14% and equal in 32%.
Anderson et al in 1982 noted ascending pattern in 43%, descending pattern 
in 5% and equal in 28% and in Ravn et al  1967 study it was ascending in 37% and 
descending in 4%.
The reflex loss by MGH series was 62% at the time of admission, 98% with 
absent ankle jerk and 80% with absent knee jerk.
Winer et al in 1988 noted that maximum deficit was reached by 34 percent 
within  7  days,  70% within  14  days  and 84 % within  21  days.   Deteroriation 
stopped by one month in 92% patients, 4% progressed further upto 44 days.
Dysautonomia  was  more  frequent  in  patients  with  severe  motor  deficits. 
Sustained sinus tachycardia and vagal mediated arrhythmia are among the most 
common cardiac complications.  Davis Dingle et al, in 1972 found hypertension in 
5-61%, hypotension in 5-57%.  They also noted quadriplegia, respiratory failure 
and  involvement  of  cranial  nerves  IX  and  X were  associated  with  orthostatic 
hypotension.
Diagnostic criteria for GBS
Diagnostic criteria for GBS  modified from AK Asbury, DR Comblath is as 
follows.
Required :
1. Progressive weakness of 2 or more limbs due to neuropathy
2. Areflexia
3. Disease course < 4 weeks
4. Exclusion  of  other  causes  (eg.  Vasculitis  (PAN,  SLE),  toxins 
(Organophosphates,  lead),  botulism,  diphtheria,  prophyria,  localized 
spinal cord or cauda equine syndrome.
Supportive :
1. Relative symmetrical weakness
2. Mild sensory involvement
3. Facial nerve or other cranial nerve involvement
4. Absence of fever
5. Typical CSF profile (acellular, increase in protein level)
6. Electrophysiological evidence of demyelinations
Variants of GBS :
The connections between these syndromes and GBS is based on  i)  a close 
resemblance to  portions of  typical  GBS  ii)  overlap between typical  GBS and 
variant  syndromes.  iii)   laboratory  findings that  confirm the diagnosis of  GBS 
particularly  raised  CSF  protein  and  electrophysiological  abnormalities.   iv) 
exclusion of other more common causes of variants.  Variants have been described 
based on topography of deficits, clinical course, fiber type involved, pathology and 
electrophysiological criteria as follows.
Topographic variants :
Miller Fisher Syndrome (MFS)
Pharyngo cervico brachial weakness
Paraparetic form
Unusual forms
Fiber type variants
Pure motor
Pure sensory
Dysautonomia
Clinical course variants
Recurrent GBS
Subacute Inflammatory Demyclinating polyneuropathy
Pathological variant
Axonal
Immunological variants of GBS
Miller Fisher Syndrome – Anti GQ lb  Ab
AMAN  -  Anti  GM 1, anti GM 1b, anti GD 1a
ASAN -  Anti GD 1b
NINCDS criteria for variants of GBS include
1. Fever at the onset of neuritic symptoms
2. Severe sensory loss with pain
3. Progression beyond four weeks
4. Sphincter involvement
5. CNS involvement
6. Sensory level
7. Very poor recovery
Miller Fisher Syndrome : 
It  constitute  5% of  all  cases  of  GBS and C-Jejuni  is  the  most  common 
trigger. Diplopia is the most common initial symptom and ataxia occurs on day 3 
to  4  and  hyporeflexia  or  areflexia  usually  occurs  at  end  of  first  week.   MFS 
pathophysiology is a subject of debate, peripheral hypothesis was put forward by 
Ropper et al in 1983 and central hypothesis by Aldin et al in 1982.
Pharyngeal Cervical Brachial Variant :
It is characterized by areflexia and abnormal electrophysiological findings 
confined to upper limbs with normal power and reflexes in legs and antibodies 
against gangliosides GT 1a and GD 1a.
Paraparetic Variant :
Areflexia and electrophysiological abnormalities are confined to lower limbs 
and CSF analysis shows albumino cytological dissociation.
Unusual topographic variants :
This includes, purely facial or oculomotor form, facial diplegia with distal 
limb paresthesia, abducent nerve palsy with distal paresthesia and severe ptosis 
without opthalmoplegia.
Axonal form :
It has fulminant onset, severe paralysis and poor recovery with characteristic 
electrophysiology.
Acute Motor Axonal Neuropathy :
Mckhann et al in 1991 described this entity in 90 patients from Northern 
China, as Chinese paralytic syndrome. Extensive wallerian like degeneration of 
motor  nerve  roots  and  motor  fibers  of  peripheral  nerves  with  extensive 
abnormalities of anterior horn cells in spinal cord characterize this.  Diagnostic 
criteria  include,  symmetric  motor  weakness  in  all  four  limbs,  absence  of 
paresthesia or sensory loss, areflexia by one week, progression of weakness by one 
day to three weeks, normal SNAP and albumino cytological dissociation in CSF.
Acute Sensory Axonal Neuropathy :
Severe  early  paresthesia  of  feet  and  hands  with  absence  of  weakness 
characteristic this.  Autopsy reveals inflammation and degeneration of dorsal root 
ganglion,   dorsal  roots  and  posterior  column  in  spinal  cord.   Antibodies  are 
directed to Ganglioside GD lb & GD3.
Pure dysantonomia :
Young and associates, in 1975 described this as a entily due to involvement 
of  myelinated  portions  of  ANS,  sympathetic  white  rami  communicans,  vagus 
nerves  and  splanchnic  nerves.   It  is  characterized  by  hypertension,  orthostatic 
hypotension,  vomiting,  diarrhea  or  constipation,  paralytic  ileus,  sweating 
disturbance and cardiac arrthymias, areflexia or hyporeflexia occurs by one week. 
Nerve  conduction  study  will  be  normal  but  CSF  shows  albuminocytological 
dissociation. Some autonomic dysfunction improves by 2-4 months.
Electro physiological profile :
Eisen et al in 1974 performed NCS at the peak of neurological deficit and 
found  58% of  patients  had  prolonged  distal  latency  and  63% had  conduction 
velocity abnormalities and in 58% SNAP were absent.
Hadden et  al  in 1998 studied 360 patients and divided the results  into 5 
groups – 69% demyelinating, 3% axonal, 3% inexcitable, 2% normal and 23% 
equirocal.   Different criteria have been used to detect demyelination by various 
authors like Albers et al 1985, Albers and Kelly 1989, Cornblath et al 1990 and 
Ho et al 1995 and as such as universally acceptable criteria. An ad hoc committee 
of the AAN included mandatory electrophysiological features as the presence of 
three  of  the  following  four  criteria  for  demyelination  :  partial  motor  nerve 
conduction  block,  reduced  motor  nerve  conduction  velocity,  prolonged  distal 
motor latencies, and prolonged F-wave latencies.
According to the American Academy of Neurology (AAN) criteria, a partial 
conduction block is a drop of 20% or more in negative peak area or peak to peak 
amplitude and a change of less than 15% in duration between proximal and distal 
sites of stimulation.  A possible conduction block or temporal dispersion is a drop 
of 20% or more in negative peak area or peak to peak amplitude and a change of 
more  than  15%  in  duration  between  proximal  and  distal  site  stimulation.   A 
reduced conduction velocity is defined as a velocity of less than 80% of the lower 
limit of the normal range if the amplitude of the CMAP is more than 80% of the 
lower limit of the normal range  or less than 70% of the lower limit, if the CMAP 
amplitude is less than 80% of the lower limit. Prolonged distal latency is defined 
as being more than 12% of the upper limit  of  the normal range if  the CMAP 
amplitude is more than 80% of the lower limit of the normal range or more than 
150% of the upper limit if the CMAP amplitude is less than 80% of the lower 
limit.  An absent F wave or F wave latency is defined as being more than125% of 
the  upper  limit  (Inflammatory  Neuropathy  Cause  and Treatment  criteria,  more 
than 120%) if the CMAP amplitude is more than 80% of the lower limit or latency 
is more than 150% of the upper limit if the CMAP amplitude is less than 80% of 
the lower limit.  The AAN Electro diagnostic Criteria requires presence of three of 
the following four conditions.  1.  Partial conduction block of >1 motor nerve,  2) 
Reduced conduction velocity of > 2 motor nerves, and 3) Prolonged distal latency 
of > 2 motor nerves, or (4) Prolonged F-wave latencies of > 2 motor nerves or the 
absence of F waves.
Albers JW, Kelly JJ et al, 1989 proposed a electrophysiologic criteria for 
Acute Demylinating poly-neuropathy as follows.
Demonstrate at least three of the following in motor nerves.
1.  Prolonged Distal Latency
 (two or more nerves not at entrapment sites)
DL  > 115% ULN (for normal CMAP amplitudes)
DL  > 125% ULN (for CMAP amplitude  < LLN)
2.  Conduction velocity slowing 
(two or more nerves not across entrapment sites)
CV < 90% LLN (for CMAP amplitudes > 50% LLN)
CV < 80% LLN (for CMAP amplitudes < 50% LLN)
3. Prolonged F and H responses (one or more nerves)
> 125% ULN
4. Conduction block or temporal dispersion (one or more nerves) 
Unequivocal conduction block :  Proximal / distal CMAP area ratio < 
0.5 
Possible conduction block :  Proximal / distal amplitude ratio < 0.7
Temporal dispersion :  Proximal / distal CMAP duration ratio  > 1.15.
Electrophysiological  studies  are  carried  out  to  support  the  diagnosis,  to 
classify the diseases and to prognosticate the GB syndrome.  Decrease in motor 
conduction  velocity  was  proved  to  be  an  adverse  prognostic  marker  in  early 
studies by Eisen et al 1974 and Pleasure et al 1968 but the study by Raman and 
Taori et al 1976 didn’t find it so.  Ropper et al 1991 reported 22 of 24 patients 
with early proximal block had quicker recovery with reversibility of block while 
those with inexcitable one or low CMAP on distal stimulation had poor outcome. 
Winer et al, in 1988 noted that 71 percent of patients with absent or small CMAP ( 
< 1 MV) from Abductor Polliscis Brevis by median nerve stimulation had delayed 
or poor recovery compared with 18 percent of patients those with large CMAP.
AIMS AND OBJECTIVES
 To study the spectrum of patients with demyelinating illness admitted in 
Govt.  Rajaji  Hospital,  Madurai  during  the  period  of  June  2007 to  April 
2009.
 To study the demographic profile of the patients with various demyelinating 
illness.
 To analyse  the  antecedent  events,  clinical  profile  and  etiological  factors 
among them.
 To evaluate  the  imaging,  CSF and electrophysiological  profile  and short 
term outcome among them.
SUBJECTS AND METHODS
The  study  design  was  prospective  one  involving  patients  admitted  in 
Medicine,  Obstetrics and Gynaecology, Neuromedicine and all  other wards for 
demyelinating illness.
Inclusion Criteria :
Patients  admitted  for  neurological  symptoms  and  signs  suggestive  of 
demyelinating illness and investigations compatible with them were included in 
study group.
Exclusion Criteria 
Patients  with  equivocal  diagnosis  or  inadequate  clinical  details  or 
investigations  not  compatible  with  demyelinating  illness  were  excluded  from 
study group.
Methodology :
Patients general information antecedent events, symptoms were recorded in 
a predesigned proforma one allotted for each patient.
Detailed clinical examination finings, pattern of weakness respiratory muscle 
weakness,  requirement  of  ventilatory  assistance  were  documented  in  that 
proforma.
CSF analysis results, neuro imaging findings, electro physiological profile 
including motor nerve conduction of standard limb nerves, F wave responses and 
Sensory Nerve Action Potential results were all recorded in the proforma. 
Statistical analysis was done on these data and Chi-Square Test, Student ‘t’ 
test and p values were applied wherever possible.
RESULTS
Total cases  with demylinating illness 
included in our study -   75.
Diagram -1
Pie Diagram showing the spectrum of distribution 
of demyelinating illnesses.
No.of 
cases
Percentage
GBS 66 88
ADEM 7 9
MS 2 3
DIAGRAM -1 
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DEMYELINATING ILLNESSES
88%
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Table – 1   
Clinical and MRI profile of two cases of M.S.
S. 
No
Parameter Case 1 Case 2
1. Age and Sex 20 F 31 F
2. Antecedent event Nil Nil
3. 1st attack Rt hemiparesis Paraparesis
4. 2nd attack Lt hemiparesis 
depression
Quadriparesis
5. Course Relapsing remitting Relapsing remitting
6. Estimated site Cerebral Spinal cord
7. MRI brain 1 Gd enhancing br 
lesion
3 periventricular 
lesions
Normal
8. MRI spinal cord
Normal
One lumbar healed 
other cervical contrast 
enhancing 
demyelinating plaque
Table – 2
Age & Sex Distribution of patients with ADEM
Age Interval Male Female Total Percentag
e
10 – 19 2 2 4 57%
20 – 29 1 1 2 29%
30 – 40 1 - 1 14%
Total 4 3 7
Males with ADEM  -  4  (57%)
Females with ADEM  -  3 (43%)
Table  -3  
 Antecent events of patients with ADEM
S. 
No.
Antecent event No.of patients Percentage
1. Exanthematous fever 2 29%
2, Post vaccinial 2 28%
3. Non specific infections 3 43%
Table – 4
Clinical and imaging profile of patients with ADEM
S. 
No.
Parameter No.of 
patients
Percentage
1. Head ache 4 57
2. Fever 3 43
3. Meningismus 4 57
4. Altered sensorium 2 29
5. Optic neuritis 1 14
6. Cranial nerve palsies 2 29
7. Pyramidal signs 6 86
8. Sensory deficits 2 29
9 Ataxia 2 29
10 Aphasia 1 14
11 Seizures 2 29
12 MRI, periventricular lesions 1 14
13 Thalamic lesions 2 29
14 Basal ganglia lesions 2 29
15 Spinal cord lesions 3 43
16 Contract enhancement 6 86
17 CSF pleocytosis 4 57
Table – 5  
Age and Sex distribution of patients with GBS
Age interval Male Female Total Percentage
10 -19 10 5 15 23
20 – 29 10 10 20 30
30 – 39 5 2 7 11
40 – 49 10 2 12 18
50 – 59 3 3 6 9
> 60 3 3 6 9
Males with GBS  -   41  (62%)
Females with GBS – 25 (38%)
Table – 6
Residential distribution of GBS cases
Residence No.of 
patients
Percentage
Madurai District 54 82
Other Districts of Tamilnadu 11 16
Other State 1 2
Table – 7
Antecent events preceeding GBS 
S. 
No.
Antecedent event No.of 
patients
% ‘t’ 
test
‘p’ 
value
1. Respiratory illness 16 24 1.49 0.1413
2. Gastrointestinal illness 6 9 2.43 0.0204
3. Malignancy 1 2 2.58 0.0153
4. Pregnancy 3 5 2.58 0.0149
5. Post viral 2 3 2.78 0.0093
6. Non specific 8 12 2.25 0.0343
Patients with GBS without any antecedent event -  30 (45%)
Table – 8
Internal between onset and peak symptoms of patients with GBS
S.No. Onset in days No.of 
patients
Percentage
1. <   7 7 10
2. 8 – 15 44 67
3. > 16 15 23
Table - 9
Signs and symptoms profile of patients with GBS
S.No. Parameter No.of patients Percentage
1 UL  weakness 60 91
2 LL weakness 62 94
3 Ophthalmoparesis 10 15
4 Facial palsy 34 51
5 Bulbar palsy 26 39
6 Sensory symptoms 48 72
7 Dysautonomia 36 54
8 Respiratory failure 26 39
9 Ventilatory assistance 23 34
       Number of patients died -  3 (5%)
Table – 10
Ventilator days of patients with GBS
Days Cases Percentage
0 – 4 8 35
4 – 8 7 30
8 – 12 6 26
> 12 2 9
Table – 11
GBS variants of this study
Variant No.of Patients Percentage
MFS 2 3
Recurrent GBS 1 1.5
Pharyngofacial 1 1.5
Bifacial 1 1.5
Table – 12
GBS patients subjected to NCS & CSF study
S.No. Investigation No.of patients Percentage
1 CSF 24 36
2 NCS 25 38
Table – 13   
CSF analysis report of patients with GBS
S.No. Parameter Normal Abnormal
1 Cells   24 0
2 Sugar 24 0
3 Protein 21 * 3
4 Globulin 24 ** 0
*  elevated (88%)
** negative 
Table – 14
Electrophysiological abnormalities  of patients with GBS
S. 
No.
Nerve F % DL % CV % CB/ 
Td
% SNAP % CMAP %
Right Median 17 68 4 16 2 8 1 4 16 64 10 40
Left Median 18 72 5 20 3 12 1 4 17 68 11 44
Right Ulnar 18 72 4 16 2 8 2 8 15 60 14 56
Left Ulnar 19 76 5 20 5 20 2 8 16 64 15 60
Right Peroneal 21 84 10 40 8 32 1 4 NA NA 12 48
Left Peroneal 21 84 8 32 7 28 1 4 NA NA 10 40
Right Tibial 19 76 8 32 10 40 3 12 NA NA 13 52
Left Tibial 19 76 11 44 10 40 4 16 NA NA 12 48
Right Sural NA NA NA NA NA NA NA NA NA NA NA NA
10 Left Sural NA NA NA NA NA NA NA NA NA NA NA NA
NA – Not applicable
Patients  with  totally  not 
stimulatable nerves  -  4 (16%)
See  Master  chart  -2  for 
abbreviations
Table – 15
Electro physiological abnormal patterns of patients with GBS
S.No. Abnormal Pattern No.of patients Percentage
1. Demyelinating 12 48
2. Axonal 4 16
3 Mixed 9 36
Table – 16
Ventilator days and outcome of GBS cases at the end of one month 
Ventilator 
days
Total Good 
recovery
% Mild – 
Moderate 
deficit
% Sever
e 
deficit
%
0 - 4 8 6 75 2 25 0 0
4 - 8 7 4 57 2 29 1 14
8 – 12 6 1 17 3 50 2 33
>12 2 0 1 50 1 50
Chi-Square value -  4.3105 ; ‘p’ value   =    0.635
Table – 17
Electrophysiological abnormality pattern and outcome of GBS cases 
at the end of one month
S.No. Abnormal 
Pattern
Total Good 
recovery
% Mild – 
Moderate 
deficit
% Sever
e 
deficit
%
1 Demyelinating 12 10 83 2 17 0 0
2 Axonal 4 0 0 1 25 3 75
3 Mixed 9 4 44 3 33 2 23
Chi square value -  0.8005 ‘p’ value    =   0.9273
DISCUSSION
Madurai  on  the  banks  of  the  Vaigai  is  one  of  the  Districts  in  South 
Tamilnadu and it spans about 3242 sq.km and it has a population of 28,54,303 
(2007).  The health services from Govt. Sector are rendered by hierarchical system 
of  Primary  Health  Centres,  Taluk  Hospitals,  ESI  hospitals  and  one  Medical 
College Hospital namely Govt. Rajaji Hospital, Madurai. (See Annexure).
Hence, GRH, Madurai is a tertiary referral care hospital to which cases not 
only from Madurai but also from nearby other districts of Tamilnadu are referred. 
The cases admitted in all the departments crosses seventy thousand per year. The 
cases  that  presents  with  acute  spectrum  of  demyelinating  illnesses  which  are 
managed with neurologists constitute 0.04 percent of admissions (2008).
In  our  23  months  of  prospective  study  75  cases  were  admitted  for 
demylinating  disorders  among  which  66  had  GBS,  7  had  ADEM  and  2  had 
multiple sclerosis.
MULTIPLE SCLEROSIS
The  two multiple  sclerosis  were  females  with  onset  in  third  decade  and 
presented with relapsing and remitting form but one was localized to intracranial 
and other to spinal  cord (Table-1).  Both had motor features and first  case had 
additional psychiatric feature, depression and second had sensory and sphincter 
problem which were  comparable to  Singhal  et  al,  and Gowrie  et  al  studies  as 
follows.
Parameters Singhal Chopra Gourie devi Murthy
Motor weakness 92.4 77.7 95.2 76.9
Sensory deficit 56 46 69 34.6
Visual loss 69 65 76.2 73
Ataxias 30 30 50 38
Sphincter dis 56 47 57 23
Occular - 11 23.8 23
ACUTE DEMYELINATING ENCEPHALO MYELITIS
Of the seven cases of ADEM, four belonged to adolescent age group and 
constituted 57 percent (Table-2).
Non specific infections contributed to 43% of antecedent events of ADEM, 
post viral and post vaccinal respectively to 29 and 14 percent (Table-3).
Pyramidal  signs  were  noted  in  86%  of  cases  of  our  study  which  has 
comparable to Scharwatz et al study 2002 (Table-4).
Meningismus was present in 57% cases of our study which was present in 
Hynson, Dale and Schwartz et al studies as 26, 31 and 15% respectively.
 Spinal cord was affected in 43% cases of our study in contrast to 16% and 
28% in Hynson and Dale et al studies.
Gadolinium enhancing lesions, indicating active lesion were present in 86% 
patients  of  our  study  in  comparable  to  90% in  Hynson  and  Dale  and  71% is 
Schwartz  study.
GULLIAN BARRE SYNDROME
Demography Profile :
82% of patients with GBS were residing at Madurai district and 16% came 
from nearby district like Virudhunagar, Theni, Dindigul and Karur and one case 
was from Iduki, Kerala (Table-6).
No month wise seasonal variation was noted in 23 months study. But the 
trend of GBS cases in 2009 seems to be increasing which needs further follow up 
in this current year (Diagram-6).
Age & Sex 
Gupta et al 1994, in their study showed the peak age group of occurrence of 
GBS in third decade, Alter et al 1990, showed the peak at fifth decade.  Dowling et 
al 1977, showed bimodal distribution. In our study, 30% of cases occurred in third 
decade followed by 23% in second decade.
Male predominance was shown in Das et al 1995 as 2.7 : 1 and Kaplan et al 
1985 as 2.1 : 1  and Alexander et al 1985 as 1.5 : 1. 
In our study 62% belonged to male group and 38% female group and male 
female ratio is 1.63 : 1 (Table-5).
Antecedent Illness 
Various studies from India showed that 30 percent to 80 percent of GBS had 
antecedent  illness.  Our  study  showed  55  percent  of  patients  had  antecedent 
illnesses which with comparison to other studies was as follows.
Antecedent event  (%) Present 
series
MGH Wiener 
1988
Italian
Respiratory illness 24 36 68 41
Gastro intestinal illness 9 8 17 8
Malignancy 2 6 - -
Pregnancy 5 12 16 4
Post viral 3 - 6 2
Non specific 12 - - 3
The  ‘p’  values  for  Gastro  intestinal  illness,  malignancy,  pregnancy,  post 
viral and non specific infections were significant (Table-7).
Clinical profile :
The highly variable sensory symptoms, 28 to 83 percent was due to varied 
criteria used for diagnosis also the incidence of autonomic dysfunction varied from 
11 to73 percent reflecting the intensity of search.
The comparison of various signs and symptoms of our study (Table-9) with 
other studies was as follows.
No. Symptoms & signs Current 
series 
(%)
MGH 
(%)
Gibbils 
(%)
Sedano
(%) 
Capro
(%) 
1. UL weakness 91 - 89 90 NA
2. LL weakness 94 98 100 97 96
3. Ophthalmoparesis 15 15 6 NA 18
4. Facial palsy 51 50 47 50 46
5. Bulbar palsy 39 40 30 26 NA
6. Sensory 72 72 79 77 46
7. Dysautonomia 54 65 73 48 13
8. Respiratory 
failure
39 34 28 13 13
9. Ventilatory 
assistance
34 5 20 13 13
Of the 23 cases that needed ventilator assistance, 8  weaned in less than 4 
days, 7 between four and eight days, 6 between eight and twelve days and 2 above 
twelve days (Table-10).
In 0-4 days group, 75% had good recovery and 25% had mild to moderate 
deficit and none had severe deficit
In  4-8  days  group,  57% had good  recovery,  29% had mild  to  moderate 
deficit and 14 percent had severe deficit
In 8-12 days group,  17% had good recovery,  50% had mild to moderate 
deficit and 33 percent had severe deficit and
In  more  than  12  days  group,  50%  had  mild  to  moderate  deficit  and 
remaining 50% had severe deficit (Table-16).
Over all mortality was attributed to the type of presentation and quality of 
intensive care and comorbid medical conditions and it varied from 2 percent to 20 
percent in Lotter et al 1977 and Gibbel et al 1992 studies respectively.  In our 
study the  mortality  was  5% and all  those  cases were  died within 24 hours  of 
admission due to respiratory failure.
Variants of GBS
The comparison of occurrence of GBS variants of our study with those of 
other studies was as follows (Table-11).
Variant (%) Current 
study
MGH Beghl Sedano
MFS 3 5 5 0.03
Recurrent GBS 1.5 0 0 0.04
Pharyngo facial 1.5 3 0 0
Bifacial 1.5 1 0 0
CSF Analysis 
Of the total admissions of patients with GBS, 36% of cases were subjected 
for CSF analysis and among them 88% showed albumino cytological dissociation 
(Table-12&13).  
Electrophysiological Study 
38% of patients admitted with GBS were subjected for nerve conduction 
studies  which  may  be  related  to  general  condition  and  availability  of 
electrophysiological lab services.  From the nerve conduction study demyelinating 
pattern was made out in 48% and axonal pattern is 16% and remaining mixed 
pattern (Table-15).
Motor nerve study of right and left median showed abnormalities of 40 and 
44 percents respectively in our study (Table-14) which was in comparison to Eisen 
et al studies which showed 25% abnormalities,  Kaur et al studies which showed 
56 percent abnormalities and  Taly et al which showed  100% abnormalities.
Motor nerve studies of ulnar showed 25%, 56%, and 47% abnormalities is 
tiesen, Kaur and Taly et al studies respectively but in our studies it was 56% in 
right ulnar, 60% in left ulnar.
Motor  nerve  studies  of  common  peroneal  showed 25%,  56% and  100% 
abnormalities in Eiesen, Kaur and Taly series respectively but in our studies it was 
48% in right peroneal and 40% in left peroneal respectively.
Right tibial and left tibial showed respectively 52% and 48% abnormalities.
F wave abnormalities were noted in 70% of median nerve studies,  74% of 
ulnar nerve studies, 84% of peroneal nerve studies, 76% of tibial nerve studies in 
our series.
Conduction block or temporal dispersion was noted in 4% of Median, 8% of 
ulnar,  4% of peroneal and 14% of tibial nerve studies in our series.
SNAP abnormalities as per Taly et al studies were 100% in median, 53% in 
ulnar and 100% in Sural stimulation.  But our studies had showed 66% in median, 
62% in ulnar, and 24 % in sural stimulation.
A short term outcome at the end of one month was analysed  (Table-17). Of 
the patients  with demyelinating abnormal pattern,  83% had good recovery and 
17% had mild to moderate deficits.  75% of axonal pattern had severe deficits and 
25% had mild to moderate deficit.  Among mixed pattern 44% had good recovery, 
33% had mild to moderate deficit and 23 percent had severe deficits.
SUMMARY AND CONCLUSIONS
 The spectrum of patients with demyelinating illness admitted comprised of 
88% GBS, followed by 9.3% ADEM and 2.7% multiple sclerosis.
 All cases of ADEM belonged to 10 to 40 year age group and 57% fell into 
adolescent age group.
 Non specific infections antedates 43% of ADEM and post viral and post 
vaccinal shared 29% and 28% respectively.
 43% of ADEM were of meningitic form and remaining encephalitic form and 
CSF pleocytosis was noted in 57% of cases
 82% of GBS cases were from Madurai  locality.  No significant variations 
between  months  of  occurrence  of  GBS  was  made  out  but  trend  is  of 
increasing pattern from this current year.
 The age group of patients with GBS varied from 10 to above 60 and 30% 
fell into third decade.  Males : Female ratio is 1.63 : 1.
 Antecedent events occurred in 55% of patients with GBS of which gastro 
intestinal illnesses constituted 9%, non specific fever  12%, pregnancy 5% 
and post viral 3% which were statistically significant.
 Lower limb onset was noted in 94% of cases and ventilator assistance was 
needed for about 34% of cases.  50% of patients in ventilator for more 
than 12 days had severe deficits which was 33% and 14% for those who 
were on ventilator for days between 8 and 12 and 4 and 8 respectively.
 Of variants, MFS occurred in 3% recurrent GBS, pharygofacial and bifacial 
occurred 1.5% each.
 36% of GBS cases were subjected to CSF study and albumino cytological 
dissociation was noted in 88%.
 Of the 38% posted for nerve conduction studies, demyelinating pattern was 
noted  in  48%  and  axonal  in  16%.   83%  of  patients  with  demyelinating 
pattern  showed  good  recovery,  whereas  75% of  axonal  pattern  showed 
severe deficit at the end of 1 month.
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PROFORMA
1. Cognitive deficit m/o/yr,  specify
2. Depression m/o/yr,   Euphoria m/o/yr,  
3. Defective vision Rt m/o/yr,   Lt m/o/yr,  Fundus
4. Restricted EOM   m/o/yr, Facial myokymia  m/o/yr,    INO m/o/yr,  
5. Facial paresis   m/o/yr, Bulbar /pseudo bulbar palsy     m/o/yr,  
6. Hemiparesis,  Rt   m/o/yr,  Spas / fla ; Lt m/o/yr,  Spas / fla
7. Paraparesis   m/o/yr,  Spas / fla ;  Sym / asym
8. Quadriparesis, UL m/o/yr,    Spas / fla ; LL   m/o/yr,  spas /fla 
9. Neck & trunk wk :      m/o/yr,  res. Difficultydays /wks ascend / not
10. Pain & temp loss, m/o/yr,   ;  level
11. Touch, vib, JPS ioss, m/o/yr,   ; level
12. Gait ataxia m/o/yr,    Limb ataxia m/o/yr,  
13. Dysarthria m/o/yr,    type
14. Bladder UMN m/o/yr,    LMN m/o/yr,   Constipation  m/o/yr,  
15. ED m/o/yr,  Others if any :  Headache / vomiting / seizures
Name   : Age  : Sex  : Hosp.No.
Residence : DOE :
16. Onset :  Acute / subacute / slow
17. Progressive    wk/mo ; then static wk/mo ; then improving   wk/mo
18. Ventilator days from    to day of illness
19. 1st episode   or    relapse  -  I / II
20. Fever – at the onset / wk/days back
21. Res. Illness days / wk back ; Diarr illness :       days/wk back
22. Chicken pox days / wk back ; measles days / wk back
23. Vaccines days / wk back  ;   specify the name  :
24. HT mo/yr  ;   DM mo/yr PT  mo/yr
25. Others if specify  :
----------------------------------------------------------------------------------------
26. MRI  brain  :
27. MRI Spinal cord  :
28. VEP
29. BERA SEP
30. 
NCS
DL Ampli CV F SNAP Comments
Rt med
Lt med
Rt uln
Lt uln
Rt pero
Lt pero
Rt 
tibial
Lt tibial
Rt sural :                     Lt Sural  :                H :             EMG :
31.  CSF  :   Cells Sugar Protein Globulin
32.  Diagnosis
a)   AIDP   b) AIDP variant, specify                 c)  ADEM   d)  MS
e)   MS, relapse   f)  Spinal MS g)  CIDP
33.   Outcome at the end of 1st month :
a)  Good recovery  b)  Mild – moderate deficit   c) severe deficit
KEY TO MASTER CHART - I
1 Hospital Number
2 Name
3 Age
16. Respiratory failure
1. Present
2. Absent
4 Sex
5 Month and year of entry
6 Residence
1.Madurai
2.Other District
3.Other State
17. Ventilator Assistance
1. Needed
2. Not needed
18. No.of days on ventilator
7. Antecedent illness
1. Respiratory illness
2. GI illness
3. Malignancy
4. Pregnancy
5. Post vital
6. Non specific
7. Nil
19. CSF status
1. CSF done with normal 
sugar and cell
2. CSF not done
20. CSF protein
1. Elevated
2. Normal
     0.  Not done
8 Onset and peak interval (in 
days)
9 Upper limb weakness
1. Present
2. Absent
21 Electrophysiological studies 
1. Done
2. Not done
10. Lower limb weakness
1. Present
2. Absent
11. Ophthalmoplegia
1. Present
2. Absent
22. Electro physiological 
abnormalities
1. Demyelinating
2. Mixed
3. Axonal
0. Not done
12. Facial palsy
1. Present
2. Absent
13. Bulbar palsy
1. Present
2. Absent
23 Ventilator days (0-4)
1.  Good recovery
2.  Mild – moderate deficit
3.  Severe deficit
0.  Not applicable
14. Sensory symptoms
1. Present
2. Absent
15. Dysarthria
1. Present
2. Absent
24 Ventilator days (4-8)
1.  Good recovery
2.  Mild – moderate deficit
3.  Severe deficit
0.  Not applicable
25 Ventilator days (8-12)
1.  Good recovery
2.  Mild – moderate deficit
3.  Severe deficit
0.  Not applicable
29 Mixed pattern and Outcome
1.  Good recovery
2.  Mild – moderate deficit
3.  Severe deficit
0.  Not applicable
26 Ventilator days (> 12)
1.  Good recovery
2.  Mild – moderate deficit
3.  Severe deficit
0.  Not applicable
30 GBS Variant
1. MFS
2. Recurrent GBS
3. Pharyngofacial
4. Bifacial
0.  Normal type
27 Demyelinating pattern and 
outcome
1.  Good recovery
2.  Mild – moderate deficit
3.  Severe deficit
0.  Not applicable
31 MRI
0 -  MRI not taken
1 – MRI with brain 
abnormalities
2 – MRI with spinal cord 
abnormalities
28 Axonal pattern and outcome
1.  Good recovery
2.  Mild – moderate deficit
3.  Severe deficit
0.  Not applicable
KEY TO MASTER CHART - II
DL Distal Latency RU Right Ulnar
CV Conduction velocity LU Left Ulnar
CB Conduction Block RP Right Peroneal
TD Temporal Dispersion LP Left Peroneal
CMAP Compound Motor 
Action potential
RT Right Tibial
SNAP Sensory Nerve 
Action Potential
LT Left Tibial
RM Right Median RS Right Sural
LM Left Median LS Left Sural
A Abnormal  as  per  AIDP 
diagnostic criteria
N Normal
0 Not obtained F F wave
ABBREVIATIONS
MS Multiple Sclerosis
CNS Central Nervous System
MRI Magnetic Resonance Imaging
CSF Cerebro Spinal Fluid
OCB Oligo Clonal Bands
IgG Immunoglobulin G
VEP Visual Evoked Potential
BAEP Brainstem Auditory Evoked Potential
SEP Somato Sensory Evoked Potential
ADEM Acute Disseminated Encephalo Myelitis
GBS Guillian Barr’e Syndrome
ADIP Acute Demyelinating Inflammatory 
Polyradiculoneuropathy
TT Tetanus Toxoide
TNF Tumour Necrosis Factor
IL Inter Leukin
MFS Miller Fisher Syndrome
AMAN Acute Motor Axonal Neuropathy
ASAN Acute Sensory Axonal Neuropathy
CMAP Compound Motor Action Potential
SNAP Sensory Motor Action Potential
ULN Upper Limit of Normal
LLN Lower Limit of Normal
DL Distal Latency
CV Conduction Velocity
PAN Poly Arteritis Nodosa
SLE Systemic Lupus Erythematosis
T2 MRI OF SPINAL CORD SHOWING CERVICAL DEMYELINATION
SAGITTAL VIEW
TRANSVERSE VIEW
MRI SPINAL CORD SHOWING MULTI FOCAL SPINAL DEMYELINATION
MOTOR NERVE CONDUCTION STUDY OF RIGHT ULNAR NERVE SHOWING 
CONDUCTION BLOCK


